AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35105643 — intervention group
Group type: COMPARATOR
Intervention: Operative treatment
Number of subjects: 68
Study 33857412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 18 doses
Number of subjects: 1019
Study 33857412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1019
Study 33857412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 18 doses in PD-L1-positive patients
Number of subjects: 1019
Study 33857412 — intervention group
Group type: COMPARATOR
Intervention: Placebo in PD-L1-positive patients
Number of subjects: 1019
Study 34254461 — intervention group
Group type: EXPERIMENTAL
Intervention: Befriending intervention, paired based on shared interests questionnaire.
Number of subjects: 16
Study 34254461 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 16
Study 33970313 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 Fr Uscope PU3033A
Number of subjects: 30
Study 33970313 — intervention group
Group type: COMPARATOR
Intervention: 9.5 Fr Uscope PU3022A
Number of subjects: 30
Study 32100358 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenated water
Number of subjects: 30
Study 32100358 — intervention group
Group type: COMPARATOR
Intervention: Control water
Number of subjects: 30
Study 36418068 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Resiliency Model (CRM) intervention, 1-hour virtual class
Number of subjects: 275
Study 36418068 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 275
Study 34455111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention modeled on MBSR combined with medical group visits (MGV)
Number of subjects: 450
Study 34455111 — intervention group
Group type: COMPARATOR
Intervention: Usual PCP care alone
Number of subjects: 450
Study 36453188 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine rectal cleansing
Number of subjects: 552
Study 36453188 — intervention group
Group type: COMPARATOR
Intervention: No povidone-iodine rectal cleansing (Control)
Number of subjects: 552
Study 34247580 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln supplementation
Number of subjects: 38
Study 34247580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HMB/Arg/Gln supplementation)
Number of subjects: 38
Study 35287025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) administered three times (median, range 1–5 times), with an interval of 9.5 months (mean [SD]) under B cell monitoring.
Number of subjects: 38
Study 35287025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) monotherapy, 28 (90%) of 31 patients treated with RTX.
Number of subjects: 38
Study 35287025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) administration under B cell monitoring.
Number of subjects: 38
Study 35287025 — intervention group
Group type: COMPARATOR
Intervention: Placebo from the RIN-1 study (control group).
Number of subjects: 38
Study 32188478 — intervention group
Group type: EXPERIMENTAL
Intervention: DIMS lenses
Number of subjects: 600
Study 32188478 — intervention group
Group type: COMPARATOR
Intervention: Apollo progressive addition lenses (PALs)
Number of subjects: 600
Study 34648182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-social messaging recruitment letters
Number of subjects: 15835
Study 34648182 — intervention group
Group type: COMPARATOR
Intervention: Financial reimbursement messaging
Number of subjects: 15835
Study 34648182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-social messaging combined with financial reimbursement
Number of subjects: 15835
Study 34648182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pro-social or financial messaging)
Number of subjects: 15835
Study 32156544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h continuous infusion)
Number of subjects: 48
Study 32156544 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 48
Study 34226291 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive pelvic and para‐aortic lymphadenectomy
Number of subjects: 640
Study 34226291 — intervention group
Group type: COMPARATOR
Intervention: Total hysterectomy plus bilateral salpingo‐oophorectomy
Number of subjects: 640
Study 32865108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical telemedicine service
Number of subjects: 203
Study 32865108 — intervention group
Group type: COMPARATOR
Intervention: Telemedicine status quo scheme
Number of subjects: 203
Study 35608639 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg)
Number of subjects: 64
Study 35608639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 33435941 — intervention group
Group type: EXPERIMENTAL
Intervention: EET (ergonomic and exercise training)
Number of subjects: 740
Study 33435941 — intervention group
Group type: COMPARATOR
Intervention: EHP (ergonomic and health promotion)
Number of subjects: 740
Study 33902498 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI based staging (arm A)
Number of subjects: 0
Study 33902498 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical staging with or without laparoscopy (arm B)
Number of subjects: 0
Study 32372588 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 0
Study 32372588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0
Study 32372588 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SCIT) and Sublingual immunotherapy (SLIT)
Number of subjects: 0
Study 35657850 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza+BCG
Number of subjects: 2615
Study 35657850 — intervention group
Group type: COMPARATOR
Intervention: Influenza
Number of subjects: 2615
Study 34648847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 388
Study 34648847 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 388
Study 34648847 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (CT)
Number of subjects: 388
Study 34648847 — intervention group
Group type: COMPARATOR
Intervention: Education class (Control)
Number of subjects: 388
Study 32961507 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress with work interruptions
Number of subjects: 90
Study 32961507 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress without work interruptions
Number of subjects: 90
Study 32961507 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no psychosocial stress)
Number of subjects: 90
Study 34024814 — intervention group
Group type: EXPERIMENTAL
Intervention: Short foot exercise group (SFEG)
Number of subjects: 30
Study 34024814 — intervention group
Group type: COMPARATOR
Intervention: Control group (ConG)
Number of subjects: 30
Study 35570699 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral SDX (120 mg)
Number of subjects: 0
Study 35570699 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral SDX (240 mg)
Number of subjects: 0
Study 35570699 — intervention group
Group type: EXPERIMENTAL
Intervention: IN SDX (80 mg)
Number of subjects: 0
Study 35570699 — intervention group
Group type: EXPERIMENTAL
Intervention: IV SDX (30 mg)
Number of subjects: 0
Study 35570699 — intervention group
Group type: COMPARATOR
Intervention: IV SDX
Number of subjects: 0
Study 35570699 — intervention group
Group type: COMPARATOR
Intervention: d-MPH (80 mg)
Number of subjects: 0
Study 35570699 — intervention group
Group type: COMPARATOR
Intervention: d-MPH (40 mg)
Number of subjects: 0
Study 35570699 — intervention group
Group type: COMPARATOR
Intervention: d-MPH (15 mg)
Number of subjects: 0
Study 33025052 — intervention group
Group type: EXPERIMENTAL
Intervention: Episealer implant
Number of subjects: 80
Study 32131748 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist shoes
Number of subjects: 64
Study 36316692 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-RRT penKid levels (penKid ≤ 89 pmol/l)
Number of subjects: 210
Study 36316692 — intervention group
Group type: COMPARATOR
Intervention: High pre-RRT penKid levels
Number of subjects: 210
Study 36316692 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-RRT penKid levels (penKid ≤ 89 pmol/l) at day 3 of RRT
Number of subjects: 210
Study 36316692 — intervention group
Group type: COMPARATOR
Intervention: High pre-RRT penKid levels at day 3 of RRT
Number of subjects: 210
Study 33308273 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic version of the Hayling Sentence Completion Test (HSCT) - Automatic condition
Number of subjects: 350
Study 33308273 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic version of the Hayling Sentence Completion Test (HSCT) - Inhibition condition
Number of subjects: 350
Study 33308273 — intervention group
Group type: EXPERIMENTAL
Intervention: Electricity as a heating method
Number of subjects: 350
Study 33308273 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher problematic mobile phone use
Number of subjects: 350
Study 33308273 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood as a heating system
Number of subjects: 350
Study 33308273 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabian incense (bakhour) as a heating method
Number of subjects: 350
Study 36409018 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg, doubled if no response at 2 weeks)
Number of subjects: 82
Study 36409018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 36409018 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 82
Study 34138850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 53787
Study 34138850 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 53787
Study 34138850 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 53787
Study 34138850 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 53787
Study 34138850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 53787
Study 34138850 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 53787
Study 34138850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 53787
Study 34138850 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 53787
Study 34138850 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 53787
Study 34138850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53787
Study 32326953 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS monitoring training module
Number of subjects: 100
Study 35363502 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise oncology program (12 weeks, aligned with ACSM guidelines)
Number of subjects: 243
Study 35363502 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard of care, resource guide)
Number of subjects: 243
Study 34091047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32996010 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Mg2+ at 0.75 mmol/L
Number of subjects: 39
Study 34410042 — intervention group
Group type: COMPARATOR
Intervention: LY2963016 (LY IGlar)
Number of subjects: 58
Study 33066944 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin therapy in combination with dynamic electric neurostimulation and basic therapy
Number of subjects: 96
Study 33066944 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin therapy and basic therapy
Number of subjects: 96
Study 33066944 — intervention group
Group type: COMPARATOR
Intervention: Dynamic electric neurostimulation and basic therapy
Number of subjects: 96
Study 33066944 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 96
Study 35654457 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 269
Study 35654457 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 269
Study 36329128 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silicone gel
Number of subjects: 153
Study 36329128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure garment
Number of subjects: 153
Study 36329128 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pressure garment and topical silicone gel therapy
Number of subjects: 153
Study 32406524 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth of a child with a major congenital anomaly
Number of subjects: 19220
Study 36461619 — intervention group
Group type: COMPARATOR
Intervention: Facemask pre-oxygenation (100% oxygen, 6 L/min)
Number of subjects: 40
Study 33351781 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (LFA3‐Ig)
Number of subjects: 0
Study 32204919 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with caudal block
Number of subjects: 60
Study 32204919 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study 35428025 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus gemcitabine plus cisplatin (GP)
Number of subjects: 0
Study 35428025 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus gemcitabine plus cisplatin (GP)
Number of subjects: 0
Study 35428025 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 0
Study 35428025 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus GP
Number of subjects: 0
Study 34506606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating protein diet (OP, 125 and 173 g/kg CP diets oscillated at 2‐d intervals)
Number of subjects: 12
Study 34506606 — intervention group
Group type: COMPARATOR
Intervention: Static protein diet (SP, 149 g/kg CP)
Number of subjects: 12
Study 34506606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating protein diet (OP) during the low protein phase
Number of subjects: 12
Study 34506606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating protein diet (OP)
Number of subjects: 12
Study 35718834 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular extraction technique
Number of subjects: 30
Study 33273376 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-QALAS with Compressed Sensing (CS)
Number of subjects: 22
Study 33273376 — intervention group
Group type: COMPARATOR
Intervention: 3D-QALAS without Compressed Sensing (CS)
Number of subjects: 22
Study 32791692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal phototherapy for 20 minutes, 3 times a week for 4 weeks
Number of subjects: 80
Study 32791692 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture for 20 minutes, 3 times a week for 4 weeks
Number of subjects: 80
Study 32791692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal phototherapy
Number of subjects: 80
Study 32711440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (400 mg/kg body weight per day)
Number of subjects: 24
Study 32711440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32711440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine
Number of subjects: 24
Study 33938492 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted lobectomy (RAL)
Number of subjects: 320
Study 34747036 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials reporting suitable baseline data
Number of subjects: 1449
Study 34747036 — intervention group
Group type: COMPARATOR
Intervention: Trials with over-representation of very small p-values
Number of subjects: 1449
Study 34747036 — intervention group
Group type: COMPARATOR
Intervention: Non-registered trials, studies supported by non-industry funding, and multi-centre RCTs
Number of subjects: 1449
Study 34544820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (1.50 mg/1.73 m2)
Number of subjects: 140
Study 34544820 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2)
Number of subjects: 140
Study 32093528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture-based empathy enhancement program
Number of subjects: 104
Study 32093528 — intervention group
Group type: COMPARATOR
Intervention: Simulation-based empathy enhancement program
Number of subjects: 104
Study 32273029 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 32877
Study 32273029 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 32877
Study 35083878 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise training (IET) group
Number of subjects: 30
Study 35083878 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 30
Study 35083878 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 30
Study 33731070 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended field of view ultrasound imaging
Number of subjects: 26
Study 32659247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful raisin-eating
Number of subjects: 71
Study 32659247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful breathing
Number of subjects: 71
Study 32659247 — intervention group
Group type: COMPARATOR
Intervention: Non-mindful control task
Number of subjects: 71
Study 35293122 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous locking with Steri-Strip (CS group)
Number of subjects: 104
Study 35293122 — intervention group
Group type: COMPARATOR
Intervention: Simple interrupted suture (SI group)
Number of subjects: 104
Study 33121452 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose clopidogrel (150 mg per day) + aspirin (100 mg per day) over 21 days
Number of subjects: 131
Study 33121452 — intervention group
Group type: COMPARATOR
Intervention: Normal dose clopidogrel (75 mg per day) + aspirin (100 mg per day) over 21 days
Number of subjects: 131
Study 33121452 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose clopidogrel + aspirin
Number of subjects: 131
Study 33121452 — intervention group
Group type: COMPARATOR
Intervention: Normal dose clopidogrel + aspirin
Number of subjects: 131
Study 36223114 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS plus D‐cycloserine (100 mg)
Number of subjects: 50
Study 36223114 — intervention group
Group type: COMPARATOR
Intervention: iTBS plus placebo
Number of subjects: 50
Study 36376812 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free home intervention (face-to-face counseling and instruction)
Number of subjects: 400
Study 36376812 — intervention group
Group type: COMPARATOR
Intervention: N/A (control group is wait-list)
Number of subjects: 400
Study 36376812 — intervention group
Group type: EXPERIMENTAL
Intervention: N/A (for PSH staff)
Number of subjects: 400
Study 32441467 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 61
Study 32441467 — intervention group
Group type: COMPARATOR
Intervention: Chlortetracycline hydrochloride ointment (Control)
Number of subjects: 61
Study 34865892 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic individual counseling
Number of subjects: 1407
Study 34865892 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic group counseling
Number of subjects: 1407
Study 34865892 — intervention group
Group type: COMPARATOR
Intervention: Phone group counseling
Number of subjects: 1407
Study 33744088 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 65
Study 33744088 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 65
Study 34870364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing unicompartmental knee arthroplasty (MB UKA)
Number of subjects: 180
Study 34870364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-bearing unicompartmental knee arthroplasty (FB UKA)
Number of subjects: 180
Study 34870364 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 180
Study 36219809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 882
Study 36219809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy
Number of subjects: 882
Study 36219809 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-course pembrolizumab
Number of subjects: 882
Study 36219809 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab-chemotherapy
Number of subjects: 882
Study 33654192 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomics ADvISER (digital decision aid)
Number of subjects: 52
Study 33654192 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 52
Study 32569355 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of ART in the hospital
Number of subjects: 801
Study 32569355 — intervention group
Group type: COMPARATOR
Intervention: Participants recruited in Southern hospitals
Number of subjects: 801
Study 35807149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting
Number of subjects: 33
Study 35807149 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 33
Study 35807149 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptives (COC)
Number of subjects: 33
Study 32473563 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12-week, 3 sessions/week) including resistance, endurance, Pilates, balance, and stretch exercises
Number of subjects: 94
Study 32473563 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 94
Study 36346817 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Written Disclosure (PWD)
Number of subjects: 0
Study 36346817 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing
Number of subjects: 0
Study 36346817 — intervention group
Group type: COMPARATOR
Intervention: No writing
Number of subjects: 0
Study 32717127 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured teaching module including intensive prophylactic measures administered by a trained oncology nurse
Number of subjects: 280
Study 32717127 — intervention group
Group type: COMPARATOR
Intervention: Standard information on HFS care administered by treating clinician (control)
Number of subjects: 280
Study 34935407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 27494